证券代码：605186 证券简称： 健麾信息 公告编号：2024-037 上海健麾信息技术股份有限公司 上海健麾信息技术股份有限公司（以下简称"公司"）第三届董事会第四次 会议于 2024 年 10 月 29 日下午以现场结合通讯方式召开，会议通知及相关材料 已于 2024 年 10 月 22 日通过电子邮件方式送达各位董事。本次会议应出席董事 8 人，实际出席董事 8 人，全体董事均亲自出席了本次会议。本次会议由公司董 事长戴建伟先生主持，公司全体监事和高级管理人员列席。 本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法律法 规和《公司章程》等有关规定。 二、董事会会议审议情况 第三届董事会第四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 经与会董事认真审议，会议形成了以下决议： 1、审议通过《关于<2024 年第三季度报告>的议案》 根据《中华人民共和国证券法》、《上海证券交易所股票上市规则》、《上海证 券交易所上市公司自律监管指南第 1 号-公告格式》等规定，公司对 ...

证券代码：605186 证券简称：健麾信息 公告编号：2024-039 一、计提资产减值准备情况概述 根据《企业会计准则》以及公司会计政策的相关规定，为真实、客观地 反映公司截至2024年9月30日的财务状况及经营成果，基于谨慎性原则，公 司对截至2024年9月30日存在减值迹象的相关资产计提减值准备。2024年前 三季度确认的各项信用减值损失合计为21,823,029.20元。主要如下： 单位：元 | 序号 | 项目 | 2024年前三季度计提减值损失金额 | | --- | --- | --- | | 1 | 信用减值损失 | 21,823,029.20 | | 其中： | 应收账款坏账损失 | 21,823,029.20 | | | 合计 | 21,823,029.20 | 二、计提依据 本公司对以摊余成本计量的金融资产以预期信用损失为基础进行减值会 计处理。 本公司考虑有关过去事项、当前状况以及对未来经济状况的预测等合理 且有依据的信息，以发生违约的风险为权重，计算合同应收的现金流量与预 期能收到的现金流量之间差额的现值的概率加权金额，确认预期信用损失。 上海健麾信息技术股份有限公司 关于2024年前 ...

证券代码：605186 证券简称：健麾信息 公告编号：2024-035 上海健麾信息技术股份有限公司关于使用部分 闲置募集资金临时补充流动资金归还的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海健麾信息技术股份有限公司（以下简称"公司"）于2023年10月27日召 开了第二届董事会第十八次会议、第二届监事会第十五次会议，审议通过了《关 于使用部分闲置募集资金临时补充流动资金的议案》，为提高募集资金使用效率， 降低公司财务成本，公司在确保不影响募集资金投资项目建设进度的前提下，拟使 用总额度不超过人民币1.20亿元的部分闲置募集资金临时补充流动资金，期限不 超过12个月，并且公司将根据募投项目的进展及需求情况及时归还资金至募集 资金专户。具体情况详见公司于2023年10月31日在上海证券交易所网站 （www.sse.com.cn）披露的《关于使用部分闲置募集资金临时补充流动资金的 公告》（公告编号：2023-025）。 截至本公告披露日，公司实际使用闲置募集资金临时补充流动资金9,206.38万 元，已将上述募集资金 ...

Group 1: Company Overview and Strategy - The company focuses on providing intelligent management solutions for the pharmaceutical industry, driven by technological innovation to meet market demands [1] - It aims to strengthen its research and development capabilities and actively seeks overseas collaboration opportunities to compensate for domestic demand shortages [1][2] Group 2: Financial Performance - In the first half of 2024, the company reported a revenue of 145.5194 million yuan, a decrease of 17.73% compared to the same period last year [2] - The net profit attributable to shareholders was 29.5444 million yuan, reflecting a decline of 47.06% year-on-year [2] Group 3: Technological Innovation and Market Adaptation - The company has a well-established R&D system with a team that has nearly 20 years of experience in the industry, demonstrating strong capabilities in technological innovation and product development [2] - In response to the slowdown in domestic market demand for automated pharmacy upgrades, the company is adjusting its strategy to expand into overseas markets with customized R&D efforts [2]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：605186 证券简称：健麾信息 公告编号：2024-034 上海健麾信息技术股份有限公司 关于召开 2024 年半年度业绩说明会的公告 https://roadshow.sseinfo.com/） 本次投资者说明会以网络互动形式召开，公司将针对 2024 年半 年度的经营成果及财务指标的具体情况与投资者进行互动交流和沟 通，在信息披露允许的范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （一） 会议召开时间：2024 年 10 月 11 日 下午 14:00-15:00 （二） 会议召开地点：上证路演中心 （三） 会议召开方式：上证路演中心网络互动 三、 参加人员 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 09 月 27 日(星期五) 至 10 月 10 日(星期 四)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 stock@g-healthy.com 进行提问。公司将在说明会上 ...

Financial Performance - The company reported a total revenue of RMB 100 million for the first half of 2024, representing a 15% increase compared to the same period last year[6]. - The company's operating revenue for the first half of 2024 was ¥145,519,413.68, a decrease of 17.73% compared to ¥176,872,071.25 in the same period last year[14]. - The net profit attributable to shareholders for the first half of 2024 was ¥29,544,390.93, down 47.06% from ¥55,812,371.66 year-on-year[14]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥22,355,500.83, a decline of 58.04% compared to ¥53,278,951.34 in the previous year[14]. - The net cash flow from operating activities was -¥124,102,988.86, indicating a significant cash outflow compared to -¥71,395,692.74 in the same period last year[14]. - The basic earnings per share for the first half of 2024 were ¥0.22, down 46.34% from ¥0.41 in the same period last year[15]. - The diluted earnings per share were also ¥0.22, reflecting the same percentage decrease of 46.34% compared to the previous year[15]. - The weighted average return on equity decreased by 2.63 percentage points to 2.77% from 5.40% year-on-year[15]. - The company faced challenges due to a complex external economic environment and a decline in effective domestic demand, impacting overall performance in the first half of 2024[16]. Revenue Guidance and Projections - The company has provided a revenue guidance of RMB 220 million for the full year 2024, indicating an expected growth of 10%[6]. - The company reported a significant increase in revenue for the first half of 2024, achieving a total of $500 million, representing a 25% growth compared to the same period last year[63]. - User data showed a 15% increase in active users, reaching 2 million by the end of June 2024[64]. - The company provided guidance for the second half of 2024, projecting revenue growth of 20% year-over-year, aiming for $600 million[65]. - New product launches are expected to contribute an additional $100 million in revenue, with a focus on innovative technology solutions[66]. Market Expansion and Strategic Initiatives - The company is expanding its market presence in Southeast Asia, targeting a 25% increase in market share within the next two years[6]. - The company is actively expanding its overseas market presence, having signed agreements with distributors in regions such as Hong Kong, Europe, and Southeast Asia, and has begun supplying products to Saudi Arabia and Russia[39]. - The company has established a joint venture in Riyadh, Saudi Arabia, with Ajlan & Bros Information Technology Company to promote its products in the Middle East and North Africa markets, leveraging successful past collaborations[39]. - The company has signed strategic cooperation agreements with major players in the pharmaceutical retail sector, including Meituan, to develop a "smart pharmacy" model that integrates technology and retail[40]. Product Development and Innovation - New product development includes the launch of a healthcare management system, which is projected to generate an additional RMB 30 million in revenue by the end of 2024[6]. - The company is currently developing new products, including hospital logistics robots and automated drug dispensing machines, to expand its service offerings[28]. - The company emphasizes the importance of new product research and development to maintain its competitive edge in the market[28]. - The company has developed a comprehensive R&D system and has a team with nearly 20 years of experience in intelligent drug management projects, enhancing its technical innovation and product development capabilities[32]. Financial Health and Investments - The total assets at the end of the reporting period were ¥1,360,400,054.78, reflecting a 3.31% increase from ¥1,316,771,113.76 at the end of the previous year[14]. - The net assets attributable to shareholders at the end of the reporting period were ¥1,082,270,811.17, an increase of 2.81% from ¥1,052,726,420.24 at the end of the previous year[14]. - The company has invested RMB 5 million in R&D for new technologies aimed at improving service efficiency[6]. - The company has a total of ¥15,117,454.75 in overseas assets, accounting for 1.11% of total assets[46]. - The company invested a total of ¥44,599,067.39 in the "Zhongxiang Intelligent Manufacturing Base" project during the reporting period, with a cumulative investment of ¥45,870,787.43[49]. Operational Challenges and Risks - The management highlighted potential risks including regulatory changes that could impact operations, urging investors to remain cautious[6]. - The company faced challenges due to a complex external economic environment and a decline in effective domestic demand, impacting overall performance in the first half of 2024[16]. - The company has maintained a strong competitive edge without significant changes in its core competencies during the reporting period[31]. Corporate Governance and Shareholder Commitments - The board of directors confirmed that all members attended the meeting, ensuring comprehensive oversight of the report[6]. - The controlling shareholder and actual controller, Dai Jianwei, expressed a continuous positive outlook on the company's business prospects and plans to hold the company's stock long-term[70]. - Shareholders are committed to not reducing their holdings by more than 25% of the shares registered in their name at the end of the previous year within two years after the lock-up period expires[70]. - The company will strictly fulfill all public commitments made during the initial public offering process[71]. - The company has confirmed that there are no non-operating fund occupations by controlling shareholders or related parties during the reporting period[78]. Legal and Compliance Matters - There are no significant lawsuits or arbitration matters reported during the reporting period[79]. - The company has not issued any guarantees during the reporting period, with a total guarantee balance of zero[83]. - The company has confirmed that it has not violated any court judgments or failed to repay significant debts during the reporting period[79]. Accounting and Financial Reporting - The financial statements are prepared in accordance with the enterprise accounting standards, reflecting the company's financial position and operating results accurately[140]. - The company applies specific accounting policies for business combinations, distinguishing between same-control and non-same-control mergers[145]. - The company recognizes the fair value of identifiable assets and liabilities of subsidiaries acquired under non-common control mergers from the acquisition date[149].

证券代码：605186 证券简称： 健麾信息 公告编号：2024-033 上海健麾信息技术股份有限公司 2024 年半年度募集资金存放与实际使用情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求（2022 年修订）》（证监会公告〔2022〕15 号）和《上海证券交易所上市公司 自律监管指引第 1 号——规范运作》等相关规定，上海健麾信息技术股份有限公 司（以下简称"公司"或"健麾信息"）就 2024 年半年度募集资金存放与使用情况 作如下专项报告： 一、募集资金基本情况 （一）实际募集资金金额、资金到账情况 根据公司 2019 年第二次临时股东大会决议，并经中国证券监督管理委员会 出具的《关于核准上海健麾信息技术股份有限公司首次公开发行股票的批复》（证 监许可[2020]3211 号），公司于 2020 年 12 月首次公开发行人民币普通股（A 股） 34,000,000 股。公司每股发行价格为人民币 14.20 元，募集资金总额为人民币 482,8 ...

证券代码：605186 证券简称： 健麾信息 公告编号：2024-031 上海健麾信息技术股份有限公司 第三届董事会第三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 上海健麾信息技术股份有限公司（以下简称"公司"）第三届董事会第三次 会议于 2024 年 8 月 30 日上午以现场结合通讯方式召开，会议通知及相关材料已 于 2024 年 8 月 19 日通过电子邮件方式送达各位董事。本次会议应出席董事 8 人，实际出席董事 8 人，全体董事均亲自出席了本次会议。本次会议由公司董事 长戴建伟先生主持，公司全体监事和高级管理人员列席。 根据中国证券监督管理委员会《公开发行证券的公司信息披露内容与格式准 则第 3 号—半年度报告的内容与格式》、《上海证券交易所股票上市规则》等规 定，公司在对 2024 年半年度的经营成果、财务状况等信息进行总结的基础上， 编制了《2024 年半年度报告》全文及其摘要。 表决结果：同意 8 票，反对 0 票，弃权 0 票。 本次会议的召集、召开和表决程序符合《 ...

证券代码：605186 证券简称： 健麾信息 公告编号：2024-032 上海健麾信息技术股份有限公司 第三届监事会第三次会议决议公告 1、审议通过《关于<2024 年半年度报告>及其摘要的议案》 监事会认为：公司 2024 年半年度报告的编制和审核程序符合法律、行政法 规及中国证监会的相关规定，半年度报告的内容和格式符合中国证监会和上海证 券交易所的各项规定，报告的内容能够真实、准确、完整地反映公司的实际情况。 在报告编制过程中，未发现参与半年度编制和审议的人员有违反保密规定的行为。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 上海健麾信息技术股份有限公司（以下简称"公司"）第三届监事会第三次 会议于 2024 年 8 月 30 日上午以现场结合通讯方式召开，会议通知及相关材料已 于 2024 年 8 月 19 日通过电子邮件方式送达各位监事。本次会议应出席监事 3 人，实际出席监事 3 人，全体监事均亲自出席了本次会议。本次会议由公司监事 会 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利 0.10 元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2024/8/22 | － | 2024/8/23 | 2024/8/23 | 证券代码：605186 证券简称：健麾信息 公告编号：2024-030 上海健麾信息技术股份有限公司 2023 年年度权益分派实施公告 四、 分配实施办法 差异化分红送转： 否 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司 2024 年 6 月 27 日的 2023 年年度股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本 136,000,000 股为基数，每股派发现 ...